Kidney Fibrosis Treatment Global Market Report 2025

Description

Kidney fibrosis treatment refers to therapeutic approaches aimed at slowing, halting, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis is the excessive buildup of extracellular matrix proteins, such as collagen, leading to scarring and a decline in kidney function, commonly associated with chronic kidney disease (CKD).

The primary treatment types for kidney fibrosis include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), pirfenidone, renin inhibitors, vasopeptidase inhibitors, and others. ACE inhibitors help lower blood pressure and reduce heart strain by blocking the enzyme that converts angiotensin I into angiotensin II. Diagnosis involves blood and urine tests, imaging scans, and kidney biopsies. These treatments are used for chronic kidney diseases, kidney cancer, and other related conditions. They are applied by various end-users, such as clinics, research centers, and hospitals.

The kidney fibrosis treatment market research report is one of a series of new reports from The Business Research Company that provides kidney fibrosis treatment market statistics, including the kidney fibrosis treatment industry's global market size, regional shares, competitors with the kidney fibrosis treatment market share, detailed kidney fibrosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kidney fibrosis treatment market. This kidney fibrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kidney fibrosis treatment market size has grown strongly in recent years. It will grow from $6.93 billion in 2024 to $7.58 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historical period can be attributed to factors such as growing research and development investments in fibrosis-targeting therapies, increasing government funding for kidney disease management initiatives, rising patient awareness of kidney transplantation and fibrosis treatment options, the expansion of healthcare infrastructure, and the growing prevalence of aging populations.

The kidney fibrosis treatment market size is expected to see rapid growth in the next few years. It will grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The projected growth in the forecast period is driven by factors including the increasing prevalence of chronic kidney diseases, rising demand for advanced therapies for renal fibrosis management, growing awareness of early-stage kidney fibrosis detection, the rising adoption of personalized medicine in kidney disease treatment, and the increasing incidence of diabetes and hypertension. Key trends in the forecast period include advancements in early detection and diagnostic tools, progress in gene therapy, the integration of technology in telemedicine and remote monitoring, advancements in stem cell therapies, and innovations in drug delivery systems.

The growing prevalence of chronic kidney disease (CKD) is expected to drive the growth of the kidney fibrosis treatment market in the coming years. CKD is a progressive loss of kidney function, often caused by conditions such as diabetes or hypertension, which lead to the accumulation of waste products in the body. The increasing rates of diabetes, which damages kidney blood vessels and impairs their ability to filter waste, are a key factor contributing to the rise in CKD. Kidney fibrosis treatments target kidney tissue scarring, reduce inflammation, and slow the progression of kidney damage, ultimately helping to preserve kidney function. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that around 14% of U.S. adults, or approximately 35.5 million people, are living with chronic kidney disease. As a result, the growing prevalence of CKD is driving the expansion of the kidney fibrosis treatment market.

The increasing number of clinical trials is also expected to fuel the growth of the kidney fibrosis treatment market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and potential side effects of medical treatments or interventions. The rising demand for personalized and innovative therapies, which require extensive testing to ensure safety and efficacy, is driving the increase in clinical trials. Kidney fibrosis treatments play a crucial role in these trials by offering a focused area for testing novel anti-fibrotic therapies, enabling researchers to evaluate the effectiveness of new drugs in slowing or even reversing kidney damage. For instance, in November 2023, the Association of the British Pharmaceutical Industry reported a 15% increase in annual recruitment to clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. As clinical trials continue to grow, so too does the demand for kidney fibrosis treatments.

In May 2023, Chinook Therapeutics, a U.S.-based biotechnology company, partnered with Ionis Pharmaceuticals, another U.S.-based biotech firm, to develop a precision therapy for chronic kidney disease. This collaboration aims to create an antisense oligonucleotide therapy targeting the genetic causes of rare, severe forms of CKD, with the goal of improving patient outcomes and reducing the need for dialysis or kidney transplants. Ionis Pharmaceuticals is also developing therapies for kidney fibrosis, including IONIS-FB-LRx, a treatment for IgA nephropathy, further highlighting the push toward innovative treatments for CKD.

Major players in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the kidney fibrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney fibrosis treatment market includes revenues earned by entities by providing services such as pharmacological treatment, diagnostic and monitoring services, and lifestyle and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Fibrosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney fibrosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney fibrosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney fibrosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors; Angiotensin Ii Receptor Blockers (Arbs); Pirfenidone; Renin Inhibitors; Vasopeptidase Inhibitors; Other Treatment Types
2) By Diagnosis: Blood Tests; Urine Tests; Imaging Tests; Kidney Biopsy
3) By Application: Chronic Kidney Diseases; Kidney Cancer Treatment; Other Applications
4) By End-User: Clinics; Research Center; Hospitals
Subsegments:
1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril; Captopri; Lisinopril; Ramipril
2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan; Telmisartan; Valsartan; Irbesartan
3) By Pirfenidone: Branded Pirfenidone; Generic Pirfenidone
4) By Renin Inhibitors: Aliskiren; Experimental Renin Inhibitors
5) By Vasopeptidase Inhibitors: Omapatrilat; Sampatrilat
6) By Other Treatment Types: Anti-Inflammatory Agents; Stem Cell Therapy; Antifibrotic Agents Under Clinical Trials; Gene Therapy
Companies Mentioned: F. Hoffman-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; AstraZeneca PLC; Cara Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35462

1. Executive Summary

2. Kidney Fibrosis Treatment Market Characteristics

3. Kidney Fibrosis Treatment Market Trends And Strategies

4. Kidney Fibrosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Kidney Fibrosis Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Kidney Fibrosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Kidney Fibrosis Treatment Market Growth Rate Analysis
5.4. Global Kidney Fibrosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Kidney Fibrosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Kidney Fibrosis Treatment Total Addressable Market (TAM)

6. Kidney Fibrosis Treatment Market Segmentation

6.1. Global Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin-Converting Enzyme (Ace) Inhibitors
Angiotensin Ii Receptor Blockers (Arbs)
Pirfenidone
Renin Inhibitors
Vasopeptidase Inhibitors
Other Treatment Types
6.2. Global Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Urine Tests
Imaging Tests
Kidney Biopsy
6.3. Global Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Kidney Diseases
Kidney Cancer Treatment
Other Applications
6.4. Global Kidney Fibrosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinics
Research Center
Hospitals
6.5. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (Ace) Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enalapril
Captopri
Lisinopril
Ramipril
6.6. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin Ii Receptor Blockers (Arbs), By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Losartan
Telmisartan
Valsartan
Irbesartan
6.7. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Pirfenidone, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded Pirfenidone
Generic Pirfenidone
6.8. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Renin Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aliskiren
Experimental Renin Inhibitors
6.9. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Vasopeptidase Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Omapatrilat
Sampatrilat
6.10. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Other Treatment Types, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Inflammatory Agents
Stem Cell Therapy
Antifibrotic Agents Under Clinical Trials
Gene Therapy

7. Kidney Fibrosis Treatment Market Regional And Country Analysis

7.1. Global Kidney Fibrosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Kidney Fibrosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kidney Fibrosis Treatment Market

8.1. Asia-Pacific Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kidney Fibrosis Treatment Market

9.1. China Kidney Fibrosis Treatment Market Overview
9.2. China Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kidney Fibrosis Treatment Market

10.1. India Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kidney Fibrosis Treatment Market

11.1. Japan Kidney Fibrosis Treatment Market Overview
11.2. Japan Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kidney Fibrosis Treatment Market

12.1. Australia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kidney Fibrosis Treatment Market

13.1. Indonesia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kidney Fibrosis Treatment Market

14.1. South Korea Kidney Fibrosis Treatment Market Overview
14.2. South Korea Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kidney Fibrosis Treatment Market

15.1. Western Europe Kidney Fibrosis Treatment Market Overview
15.2. Western Europe Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kidney Fibrosis Treatment Market

16.1. UK Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kidney Fibrosis Treatment Market

17.1. Germany Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kidney Fibrosis Treatment Market

18.1. France Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kidney Fibrosis Treatment Market

19.1. Italy Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kidney Fibrosis Treatment Market

20.1. Spain Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kidney Fibrosis Treatment Market

21.1. Eastern Europe Kidney Fibrosis Treatment Market Overview
21.2. Eastern Europe Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kidney Fibrosis Treatment Market

22.1. Russia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kidney Fibrosis Treatment Market

23.1. North America Kidney Fibrosis Treatment Market Overview
23.2. North America Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kidney Fibrosis Treatment Market

24.1. USA Kidney Fibrosis Treatment Market Overview
24.2. USA Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kidney Fibrosis Treatment Market

25.1. Canada Kidney Fibrosis Treatment Market Overview
25.2. Canada Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kidney Fibrosis Treatment Market

26.1. South America Kidney Fibrosis Treatment Market Overview
26.2. South America Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kidney Fibrosis Treatment Market

27.1. Brazil Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kidney Fibrosis Treatment Market

28.1. Middle East Kidney Fibrosis Treatment Market Overview
28.2. Middle East Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kidney Fibrosis Treatment Market

29.1. Africa Kidney Fibrosis Treatment Market Overview
29.2. Africa Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kidney Fibrosis Treatment Market Competitive Landscape And Company Profiles

30.1. Kidney Fibrosis Treatment Market Competitive Landscape
30.2. Kidney Fibrosis Treatment Market Company Profiles
- 30.2.1. F. Hoffman-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Cara Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Kidney Fibrosis Treatment Market Other Major And Innovative Companies

31.1. Gilead Sciences Inc.
31.2. Novo Nordisk A/S
31.3. Boehringer Ingelheim International GmbH
31.4. Vertex Pharmaceuticals Incorporated
31.5. Chinook Therapeutics Inc.
31.6. Reata Pharmaceuticals Inc.
31.7. Akebia Therapeutics Inc.
31.8. Travere Therapeutics Inc.
31.9. Insilico Medicine Inc.
31.10. Tvardi Therapeutics Inc.
31.11. ProKidney LLC
31.12. Alentis Therapeutics AG
31.13. La Jolla Pharmaceutical Company
31.14. Galecto Biotech AB
31.15. Purespring Therapeutics Inc.

32. Global Kidney Fibrosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kidney Fibrosis Treatment Market

34. Recent Developments In The Kidney Fibrosis Treatment Market

35. Kidney Fibrosis Treatment Market High Potential Countries, Segments and Strategies

35.1 Kidney Fibrosis Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Kidney Fibrosis Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Kidney Fibrosis Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer